GenScript PROBIO
A Global CDMO from GenScript Group

Webinar - Unlocking Affordability:

Cell Therapy Development Strategies to Expand Patient Access

Time: 15:00-16:30 (GMT+8), 28th March

The current global market of cell and gene therapies (CGT) is valued over $ 15 billion. This is expected to grow at rate of nearly 20% every year from 2022 to 2032 and reaches over $80 billion within a decade. Both plasmids and viral vectors have emerged as the key players in this field. Join us to learn innovative approaches to accelerate your cell therapy development and reduce costs while enhancing quality to benefit more patients.

Topic 1:

Utilization of VHH phage display library & integrated protein engineering platform to generate antibody leads for CAR-T therapy

Dr. Li Chen, Sr. Director, Biologics Discovery Dept. GenScript ProBio

- General consideration and workflow of CAR lead discovery
- Detail introduction of antibody discovery platform for cell therapy
- Case study of anti-CD7 and anti-ROR1 CAR lead discovery

Topic 2:

Accelerating the development of the cell therapies via manufacturing high-quality plasmids and high-titer viral vectors

Dr. Ming Ni, Sr. Technical Lead, GenScript ProBio

- How to enhance the quality of plasmids for CAR-T cell therapy manufacturing
- How to maximize lentiviral vector titers for CAR-T cell therapy
- Fast CMC and fast manufacturing with accelerating lentiviral vector development cycle

Register Now

Best Regards,

GenScript ProBio
Email: cdmo.kr@genscriptprobio.com
Web: www.genscriptprobio.com

GenScript ProBio Kakao Channel